GlassScriptPhysician profile
Jonnathan Soltero
NPI 1376068940
$2,971.70
in general payments reported to CMS, 2019-2025
20 companies · $332 in 2025
The $332 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,051 · 2022: $531 · 2023: $630 · 2024: $428 · 2025: $332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,389.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $507.16 | 2021-2024 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $330.49 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $312.20 | 2022-2025 | |
| Lilly USA, LLC | $242.49 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $224.36 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $222.37 | 2022-2025 | |
| Amarin Pharma, INC. | $172.49 | 2021-2022 | |
| Amgen INC. | $152.00 | 2021-2025 | Krystexxa |
| Janssen Pharmaceuticals, INC | $150.21 | 2021-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.64 | 2021-2025 | Jardiance |
| Abbott Laboratories | $110.10 | 2021-2025 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $108.02 | 2021 | |
| Sanofi-Aventis U.S. LLC | $54.62 | 2022 | |
| Exact Sciences Corporation | $51.32 | 2023-2025 | Cologuard Collection Kit |
| Edwards Lifesciences Corporation | $50.78 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $50.13 | 2023 | Collagenase Santyl |
| Astellas Pharma US INC | $44.27 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $41.85 | 2024-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $16.63 | 2022 | |
| Gilead Sciences, INC. | $16.57 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonnathan Soltero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.